A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (HORIZON 2)

  • STATUS
    Recruiting
  • End date
    Dec 3, 2024
  • participants needed
    300
  • sponsor
    Janssen Vaccines & Prevention B.V.
Updated on 11 August 2022
Accepts healthy volunteers

Summary

The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents (Part 1 and Part 2); and to demonstrate non-inferiority (NI) of immune responses induced by 1 dose or 2 doses or of a lower, to be determined, dose level of Ad26.COV2.S in adolescents versus 1 or 2 doses of Ad26.COV2.S (Part 2).

Description

Available safety, immunogenicity and efficacy data from the Ad26.COV2.S vaccine development program supports initiating evaluation of Ad26.COV2.S in the pediatric population. Ad26.COV2.S will be evaluated in the pediatric population through a dose-confirmation approach. Ad26.COV2.S (also known as Ad26COVS1, VAC31518, JNJ-78436735) is a monovalent vaccine composed of a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector, constructed to encode the severe acute respiratory syndrome coronavirus(-2) (SARS-CoV-2) spike (S) protein, stabilized in its prefusion conformation. The Part 1 study duration from screening until the last follow-up visit will be, excluding the 28-day screening phase, up to 18 months (Groups 1-3) and 26 months (Groups 4-6) for Part 1, consisting of study period (6-months) including vaccination with a 1 active dose and a placebo vaccination (56-day interval) and a booster vaccination at 6 months (Groups 1-3) and a 12-months study period with 2 active doses (56-day interval) and a booster vaccination at 12 months and follow-up (safety and immunogenicity) until 12 months after respective booster vaccination (Groups 4-6). The Part 2 study duration from screening until the last follow-up visit will be, excluding the 28-day screening phase, up to 12-22 months, consisting of study period (up to 12 months) including vaccination with a 1 or 2-dose (56-day interval) regimen, and follow-up safety and immunogenicity) until 12 months after last vaccination in the primary regimen, and up to 14 months for the 2-dose regimen (12 months after the second vaccination). Assessments like immunogenicity (such as humoral and cellular immune responses), safety and reactogenicity (such as adverse events [AEs] monitoring) will be performed in this study. Other safety assessments include vital signs measurements (heart rate, supine systolic and diastolic blood pressure, respiratory rate, and body temperature) and physical examinations. The overall study duration from enrolment of the first participant until study completion is expected to be up to 3 year 2 months.

Details
Condition Coronavirus Disease-2019 (COVID-19) Prevention
Treatment Ad26.COV2.S
Clinical Study IdentifierNCT05007080
SponsorJanssen Vaccines & Prevention B.V.
Last Modified on11 August 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant's age is 12 to 17 years of age at the time of first vaccination
Participant must be healthy, in the investigator's clinical judgement, as confirmed by medical history, physical examination, and vital signs performed at screening, and must not have comorbidities related to an increased risk of severe coronavirus disease-2019 (COVID-19)
Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine
Participant and/or parent(s)/legal guardian(s) are available and willing to participate for the duration of the study visits and follow-up
Each participant or participant's parent(s)/legal guardian(s) must have access to a consistent means of contact either by telephone contact or email/computer

Exclusion Criteria

Participant has a history of malignancy, bone marrow transplant, or solid organ transplant within 5 years before screening
Participant has a known or suspected allergy, history of anaphylaxis, or other serious adverse reactions, related to vaccines or their excipients (including specifically the excipients of the study vaccine)
Use of systemic corticosteroids at an immunosuppressive dose (treatment duration more than 14 days for one course or recurrent use) within 6 months before administration of study vaccine and during the study
Participants with a history of illness or with an ongoing illness that, in the opinion of the investigator, may pose additional risk to the participant if he/she participates in the study
Any serious, chronic, or progressive disease (example: diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, acquired immunodeficiency syndrome [AIDS] infection, blood dyscrasias, bleeding diathesis, signs of cardiac or renal failure, or severe malnutrition)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note